Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis

Journal of Infection and Public Health

Volumn 7, Issue 2, 2014, Pages 75-91

  Ahmad, Suhail ^a   Mokaddas, Eiman ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Diagnosis; Multidrug resistant tuberculosis; New drugs; Treatment; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLAVULANIC ACID; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; IMIPENEM; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; MYCOLIC ACID; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLONE DERIVATIVE; RIFAMPICIN; STREPTOMYCIN; TERIZIDONE; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VIOMYCIN;

BACTERIAL STRAIN; DEVELOPING COUNTRY; DRUG MECHANISM; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MIXED INFECTION; MOLECULAR DIAGNOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT REFUSAL; TREND STUDY; TUBERCULOSIS;

DIAGNOSIS; MULTIDRUG-RESISTANT TUBERCULOSIS; NEW DRUGS; TREATMENT; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIOLOGICAL TECHNIQUES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84896072874     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2013.09.001     Document Type: Review

References (86)

1. Ahmad S. New approaches in the diagnosis and treatment of latent tuberculosis infection. Respiratory Research 2010, 11:169.
2. World Health Organization Global tuberculosis report 2012. WHO report 2012. WHO/HTM/TB/2008.393 2012, 1-393. WHO, Geneva, Switzerland.
3. Pawlowski A., Jansson M., Sköld M., Rottenberg M.E., Källenius G. Tuberculosis and HIV co-infection. PLoS Pathogens 2012, 8:e1002464.
4. Mokaddas E., Ahmad S., Samir I. Secular trends in susceptibility patterns of Mycobacterium tuberculosis isolates in Kuwait, 1996-2005. International Journal of Tuberculosis and Lung Disease 2008, 12:319-325.
5. Harries A.D., Lin Y., Satyanarayana S., Lönnroth K., Li L., Wilson N., et al. The looming epidemic of diabetes-associated tuberculosis: learning lessons from HIV-associated tuberculosis. International Journal of Tuberculosis and Lung Disease 2011, 15:1436-1444.
6. Palomino J.C., Martin A., Von Groll A., Portaels F. Rapid culture-based methods for drug-resistance detection in Mycobacterium tuberculosis. Journal of Microbiological Methods 2008, 75:161-166.
7. Wright A., Zignol M., Van Deun A., Falzon D., Gerdes S.R., Feldman K., et al. Epidemiology of antituberculosis drug resistance 2002-2007: an updated analysis of the global project on anti-tuberculosis drug resistance surveillance. Lancet 2009, 373:1861-1873.
8. World Health Organization Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response. WHO/HTM/TB/2010.3 2010, WHO, Geneva, Switzerland.
9. Drobniewski F., Nikolayevskyy V., Balabanova Y., Bang D., Papaventsis D. Diagnosis of tuberculosis and drug resistance: what can new tools bring us?. International Journal of Tuberculosis and Lung Disease 2012, 16:860-870.
10. Palomino J.C. Current developments and future perspectives for TB diagnostics. Future Microbiology 2012, 7:59-71.
11. Boehme C.C., Nabeta P., Hillemann D., Nicol M.P., Shenai S., Krapp F., et al. Rapid molecular detection of tuberculosis and rifampin resistance. New England Journal of Medicine 2010, 363:1005-1015.
12. Chang K., Lu W., Wang J., Zhang K., Jia S., Li F., et al. Rapid and effective diagnosis of tuberculosis and rifampicin resistance with Xpert MTB/RIF assay: a meta-analysis. Journal of Infection 2012, 64:580-588.
13. Blumberg H.M., Burman W.J., Chaisson R.E., Daley C.L., Etkind S.C., Friedman L.N., et al. Treatment of tuberculosis. American Journal of Respiratory and Critical Care Medicine 2003, 167:603-662.
14. Jiménez-Corona M.E., Cruz-Hervert L.P., García-García L., Ferreyra-Reyes L., Delgado-Sánchez G., Bobadilla-Del-Valle M., et al. Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax 2013, 68:214-220.
15. Mitchison D., Davies G. The chemotherapy of tuberculosis: past, present and the future. International Journal of Tuberculosis and Lung Disease 2012, 16:724-732.
16. Orenstein E.W., Basu S., Shah N.S., Andrews J.R., Friedland G.H., Moll A.P., et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infectious Diseases 2009, 9:153-161.
17. Ahmad S., Mokaddas E. New approaches in the diagnosis and treatment of susceptible, multidrug-resistant and extensively drug-resistant tuberculosis. Kuwait Medical Journal 2012, 44:3-19.
18. Gandhi N.R., Andrews J.R., Brust J.C.M., Montreuil R., Weissman D., Heo M., et al. Risk factors for mortality among MDR- and XDR-TB patients in a high HIV prevalence setting. International Journal of Tuberculosis and Lung Disease 2012, 16:90-97.
19. Johnson J.L., Hadad D.J., Boom W.H., Daley C.L., Peloquin C.A., Eisenach K.D., et al. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. International Journal of Tuberculosis and Lung Disease 2006, 10:605-612.
20. Cox H., Ford N. Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis. International Journal of Tuberculosis and Lung Disease 2012, 16:447-454.
21. Dooley K.E., Obuku E.A., Durakovic N., Belitsky V., Mitnick C., Nuermberger E.L. World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?. Journal of Infectious Diseases 2013, 207:1352-1358.
22. Gonzalo X., Drobniewski F. Is there a place for β-lactams in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis? Synergy between meropenem and amoxicillin/clavulanate. Journal of Antimicrobial Chemotherapy 2013, 68:266-269.
23. Zhang Y., Heym B., Allen B., Young D., Cole S.T. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992, 358:591-593.
24. Almeida Da Silva P.E., Palomino J.C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. Journal of Antimicrobial Chemotherapy 2011, 66:1417-1430.
25. Ahmad S., Mokaddas E. Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East. International Journal of Antimicrobial Agents 2004, 23:473-479.
26. Al-Mutairi N., Ahmad S., Mokaddas E. Performance comparison of four methods for rapid detection of multidrug-resistant Mycobacterium tuberculosis strains. International Journal of Tuberculosis and Lung Disease 2011, 15:110-115.
27. Telenti A., Imboden P., Marchesi F., Lowrie D., Cole S., Colston M.J., et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993, 341:647-650.
28. Comas I., Borrell S., Roetzer A., Rose G., Malla B., Kato-Maeda M., et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nature Genetics 2011, 44:106-110.
29. Tan Y., Hu Z., Zhao Y., Cai X., Luo C., Zou C., et al. The beginning of the rpoB gene in addition to the rifampin resistance determination region might be needed for identifying rifampin/rifabutin cross-resistance in multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. Journal of Clinical Microbiology 2012, 50:81-85.
30. Scorpio A., Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidedase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nature Medicine 1996, 2:662-667.
31. Shi W., Zhang X., Jiang X., Yuan H., Lee J.S., Barry C.E., 3rd, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 2011, 333:1630-1632.
32. Telenti A., Phillipp W., Sreevatsan S., Bernasconi C., Stockbauer K.E., Wieles B., et al. The emb operon, a unique gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol. Nature Medicine 1997, 3:567-570.
33. Ahmad S., Jaber A.-A., Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and -resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis (Edinburgh) 2007, 87:123-129.
34. Sreevatsan S., Pan X., Stockbauer K.E., Williams D.L., Kreisworth B.N., Musser J.M. Characterization of rpsL and rrs mutations in streptomycin-resistant Mycobacterium tuberculosis isolates from diverse geographic localities. Antimicrobial Agents and Chemotherapy 1996, 40:1024-1026.
35. Spies F.S., Ribeiro A.W., Ramos D.F., Ribeiro M.O., Martin A., Palomino J.C., et al. Streptomycin resistance and lineage-specific polymorphisms in Mycobacterium tuberculosis gidB gene. Journal of Clinical Microbiology 2011, 49:2625-2630.
36. Georghiou S.B., Magana M., Garfein R.S., Catanzaro D.G., Catanzaro A., Rodwell T.C. Evaluation of genetic mutations associated with Mycobacterium tuberculosis resistance to amikacin, kanamycin and capreomycin: a systematic review. PLoS ONE 2012, 7:e33275.
37. Dalton T., Cegielski P., Akksilp S., Asencios L., Caoili J.C., Cho S.-N. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study. Lancet 2012, 380:1406-1417.
38. Juréen P., Angeby K., Sturegård E., Chryssanthou E., Giske C.G., Werngren J., et al. Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections. Journal of Clinical Microbiology 2010, 48:1853-1858. http://www.ncbi.nlm.nih.gov/pubmed/20237102.
39. Rieder H.L. Fourth-generation fluoroquinolones against tuberculosis. Lancet 2009, 373:1148-1149.
40. Sirgel F.A., Warren R.M., Streicher E.M., Victor T.C., van Helden P.D., Böttger E.C. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. Journal of Antimicrobial Chemotherapy 2012, 67:1088-1093.
41. Siddiqi S., Ahmed A., Asif S., Behera D., Javaid M., Jani J., et al. Direct drug susceptibility testing of Mycobacterium tuberculosis for rapid detection of multidrug resistance using the Bactec MGIT 960 system: a multicenter study. Journal of Clinical Microbiology 2012, 50:435-440.
42. Moore D.A., Shah N.S. Alternative methods of diagnosing drug resistance, what can they do for me?. Journal of Infectious Diseases 2011, 204(Suppl 4):S1110-S1119.
43. Lee A.S., Ong D.C. Molecular diagnostic methods for the detection of Mycobacterium tuberculosis resistance: the potential of high-resolution melting analysis. Expert Reviews on Anti Infective Therapy 2012, 10:1075-1077.
44. Choi J.H., Lee K.W., Kang H.R., Hwang Y.I., Jang S., Kim D.G., et al. Clinical efficacy of direct DNA sequencing analysis on sputum specimens for early detection of drug-resistant Mycobacterium tuberculosis in a clinical setting. Chest 2010, 137:393-400.
45. Casali N., Nikolayevskyy V., Balabanova Y., Ignatyeva O., Kontsevaya I., Harris S.R., et al. Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Research 2012, 22:735-745.
46. ® MTBDRPlus assay in routine settings: a multicenter study. European Journal of Clinical Microbiology and Infectious Diseases 2012, 31:1381-1387.
47. Lacoma A., García-Sierra N., Prat C., Maldonado J., Ruiz-Manzano J., Haba L., et al. GenoType MTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples. Journal of Clinical Microbiology 2012, 50:30-36.
48. Barnard M., Warren R., Van Pittius N.G., van Helden P., Bosman M., Streicher E., et al. GenoType MTBDRsl line probe assay shortens time to diagnosis of XDR-TB in a high-throughput diagnostic laboratory. American Journal of Respiratory and Critical Care Medicine 2012, 186:1298-1305.
49. Furin J. The clinical management of drug-resistant tuberculosis. Current Opinion in Pulmonary Medicine 2007, 13:212-217.
50. Menzies D., Benedetti A., Paydar A., Royce S., Madhukar P., Burman W., et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistant to isoniazid: a systematic review and meta-analysis. PLoS Medicine 2009, 6:e1000150.
51. Yee D.P., Menzies D., Brassard P. Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec. International Journal of Tuberculosis and Lung Disease 2012, 16:604-609.
52. Lew W., Pai M., Oxlade O., Martin D., Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Annals of Internal Medicine 2008, 149:123-134.
53. Caminero J.A., Sotgiu G., Zumla A., Migliori G.B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infectious Diseases 2010, 10:621-629.
54. Van Deun A., Maug A.K., Salim M.A., Das P.K., Sarker M.R., Daru P., Rieder H.L. Short, highly effective and inexpensive standardised treatment of multidrug-resistant tuberculosis. American Journal of Respiratory and Critical Care Medicine 2010, 182:684-692.
55. Gegia M., Kalandadze I., Kempker R.R., Magee M.J., Blumberg H.M. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. International Journal of Infectious Diseases 2012, 16:e391-e396.
56. Johnston J.C., Shahidi N.C., Sadatsafavi M., Fitzgerald J.M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009, 4:e6914.
57. Ahuja S.D., Ashkin D., Avendano M., Banerjee R., Bauer M., Bayona J.N., et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Medicine 2012, 9:e1001300.
58. Jacobson K.R., Tierney D.B., Jeon C.Y., Mitnick C.D., Murray M.B. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clinical Infectious Diseases 2010, 51:6-14.
59. Amaral L., Viveiros M. Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections. International Journal of Antimicrobial Agents 2012, 39:376-380.
60. Seddon J.A., Hesseling A.C., Marias B.J., McIlleron H., Peloquin C.A., Donald P.R., et al. Pediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinburgh) 2012, 92:9-17.
61. Wells C.D. Global impact of multidrug-resistant pulmonary tuberculosis among HIV-infected and other immunocompromised hosts: epidemiology, diagnosis, and strategies for management. Current Infectious Disease Reports 2010, 12:192-197.
62. Arentz M., Pavlinac P., Kimerling M.E., Horne D.J., Falzon D., Schünemann H.J., et al. Use of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic review. PLoS ONE 2012, 7:e47370. http://www.ncbi.nlm.nih.gov/pubmed/23144818.
63. Satti H., McLaughlin M.M., Hedt-Gauthier B., Atwood S.S., Omotayo D.B., Ntlamelle L., et al. Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho. PLoS ONE 2012, 7:e46943. http://www.ncbi.nlm.nih.gov/pubmed/23115633.
64. Palomino J.C., Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis?. Journal of Antimicrobial Chemotherapy 2013 Feb, 68(2):275-283.
65. Grosset J.H., Singer T.G., Bishai W.R. New drugs for the treatment of tuberculosis: hope and reality. International Journal of Tuberculosis and Lung Disease 2012, 16:1005-1014.
66. Steingart K.R., Jotblad S., Robsky K., Deck D., Hopewell P.C., Huang D., et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. International Journal of Tuberculosis and Lung Disease 2011, 15:305-316.
67. Sekiguchi J., Disratthakit A., Maeda S., Doi N. Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone. Antimicrobial Agents and Chemotherapy 2011, 55:3958-3960.
68. Ahmad Z., Minkowski A., Peloquin C.A., Williams K.N., Mdluli K.E., Grosset J.H., et al. Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrobial Agents and Chemotherapy 2011, 55:1781-1783.
69. Sharma S., Singh A. Phenothiazines as anti-tubercular agents: mechanistic insights and clinical implications. Expert Opinion in Investigational Drugs 2011, 20:1665-1676.
70. Dhillon J., Andries K., Phillips P.P.J., Mitchison D.A. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinburgh) 2010, 90:301-305.
71. Diacon A.H., Donald P.R., Pym A., Grobusch M., Patientia R.F., Mahanyele R., et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrobial Agents and Chemotherapy 2012, 56:3271-3276.
72. Diacon A.H., Dawson R., von Groote-Bidlingmaier F., Symons G., Venter A., Donald P.R., et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 2012, 380:986-993.
73. Mukherjee T., Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future. Future Medicinal Chemistry 2011, 3:1427-1454.
74. Tasneen R., Li S.Y., Peloquin C.A., Taylor D., Williams K.N., Andries K., et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy 2011, 55:5485-5492. http://www.ncbi.nlm.nih.gov/pubmed/21930883.
75. Gler M.T., Skripconoka V., Sanchez-Garavito E. Delamanid for multidrug-resistant pulmonary tuberculosis. New England Journal of Medicine 2012, 366:2151-2160.
76. Nikonenko B.V., Protopopova M.N., Samala R., Einck L., Nacy C.A. Drug therapy of experimental TB: improved outcome by combining SQ109, a new diamine antibiotic with existing TB drugs. Antimicrobial Agents and Chemotherapy 2007, 51:1563-1565.
77. Reddy V.M., Dubuisson T., Einck L., Wallis R.S., Jakubiec W., Ladukto L., et al. SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro. Journal of Antimicrobial Chemotherapy 2012, 67:1163-1166.
78. Shaw K.J., Barbachyn M.R. The oxazolidinones: past, present, and future. Annals of the New York Academy of Sciences 2011, 1241:48-70.
79. Williams K.N., Brickner S.J., Stover C.K., Zhu T., Ogden A., Tasneen R., et al. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. American Journal of Respiratory and Critical Care Medicine 2009, 180:371-376.
80. Williams K., Minkowski A., Amoabeng O., Peloquin C.A., Taylor D., Andries K., et al. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrobial Agents and Chemotherapy 2012, 56:3114-3120.
81. Makarov V., Manina G., Mikusova K., Möllmann U., Ryabova O., Saint-Joanis B., et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009, 324:801-804.
82. Lechartier B., Hartkoorn R.C., Cole S.T. In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 2012, 56:5790-5793.
83. Christophe T., Jackson M., Jeon H.K., Fenistein D., Contreras-Dominguez M., Kim J., et al. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathogens 2009, 5:e1000645.
84. Bogatcheva E., Hanrahan C., Nikonenko B., de los Santos G., Reddy V., Chen P., et al. Identification of SQ609 as a lead compound from a library of dipiperidines. Bioorganic and Medicinal Chemistry Letters 2011, 21:5353-5357. http://www.ncbi.nlm.nih.gov/pubmed/21807506.
85. Bogatcheva E., Dubuisson T., Protopopova M., Einck L., Nacy C.A., Reddy V.M. Chemical modification of capuramycins to enhance antibacterial activity. Journal of Antimicrobial Chemotherapy 2011, 66:578-587. http://www.ncbi.nlm.nih.gov/pubmed/21186194.
86. Hirano S., Ichikawa S., Matsuda A. Structure-activity relationship of truncated analogs of caprazamycins as potential anti-tuberculosis agents. Bioorganic and Medicinal Chemistry 2008, 16:5123-5133.